drugset
Drugs / EF5
last change Aug 2015 re-read 2 minutes ago

EF5

also known as NSC#684681 · 18F-EF5 · fluorine F 18 EF5

Diagnostic / imaging agent

Investigated by
National Cancer Institute (NCI) · David M. Brizel, MD · Duke University · Gynecologic Oncology Group · Mark Dewhirst · National Institutes of Health (NIH)
+2 more · Stanford University · University Health Network, Toronto

Trials 12 · a red edge is where a trial was stopped

today NCT01123005 · Ph 1 NCT01055678 · Ph 0 NCT00110032 · Ph 1 NCT00107445 · Ph 2 NCT00087191 · not/applicable NCT00049231 · not/applicable NCT00049140 · Ph 2 NCT02154399 · Ph 2 NCT00041028 · Ph 2 NCT00896961 · not/applicable NCT00004261 · Ph 1 NCT00003282 · Ph 1
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01055678 Jan 2010 → Dec 2011 breast cancer Mark Dewhirst Withdrawn No outcome recorded
Phase 14 trials
Phase 1 NCT01123005 Dec 2010 → Aug 2015 neoplasm Stanford University Terminated No outcome recorded
Phase 1 NCT00110032 Jun 2005 → Jan 2007 adult anaplastic ependymoma, adult brain ependymoma, adult brainstem glioma, adult central nervous system germ cell tumor +22 National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00004261 Dec 1999 → Jun 2002 breast cancer, cervical cancer, head and neck cancer, prostate cancer +1 University Health Network, Toronto Terminated No outcome recorded
Phase 1 NCT00003282 Mar 1998 → May 2005 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 24 trials
Phase 2 NCT00107445 Feb → Sep 2005 cervical carcinoma, endometrial carcinoma, malignant epithelial tumor of ovary, peritoneal carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00049140 Aug 2002 → Oct 2004 head and neck cancer David M. Brizel, MD Completed No outcome recorded
Phase 2 NCT02154399 May 2002 → Sep 2007 non-small cell lung carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00041028 May 2002 → Sep 2007 lung cancer Duke University Completed No outcome recorded
Phase not applicable3 trials
— NCT00087191 May 2004 → Jan 2006 appendix carcinoma, carcinoid tumor, exocrine pancreatic carcinoma, extrahepatic bile duct carcinoma +16 National Cancer Institute (NCI) Terminated No outcome recorded
— NCT00049231 Jun 2003 → Aug 2005 cervical cancer Gynecologic Oncology Group Completed No outcome recorded
— NCT00896961 Aug 2001 → Sep 2007 lip and oral cavity squamous cell carcinoma, soft tissue sarcoma National Cancer Institute (NCI) Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as EF5 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00049140 ↗
11

NCT01123005 ↗

NCT00896961 ↗

NCT00004261 ↗

NCT00041028 ↗

NCT01055678 ↗

NCT00107445 ↗

NCT00049231 ↗

NCT00087191 ↗

NCT00110032 ↗

NCT02154399 ↗

NCT00003282 ↗
Known as 18F-EF5 “Patients receive fluorine F 18 EF5 (\^18F-EF5) IV followed by whole brain and whole body positron emission tomography (PET) scanning OR whole body PET scanning only.” NCT00110032 ↗
Known as fluorine F 18 EF5 “Patients receive fluorine F 18 EF5 (\^18F-EF5) IV followed by whole brain and whole body positron emission tomography (PET) scanning OR whole body PET scanning only.” NCT00110032 ↗
Known as NSC#684681 “A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas” NCT00004261 ↗
1

“Evaluation of Hypoxia by EF5 (NSC#684681) Binding in Cervix Cancer” NCT00049231 ↗
Modality Diagnostic / imaging agent “Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells” NCT00003282 ↗
Route Intravenous “EF5 IV over 1-2 hours” NCT00003282 ↗